RP Cure Tracker

Trials / NCT05809635

Study of BEST1 Vitelliform Macular Dystrophy

Recruiting now Observational Natural history / observational

Sponsor
Columbia University
Treatment
Natural History Study
Gene
BEST1
Conditions
Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
Ages
Any to no upper limit
Enrollment
52 participants
Started
2021-03-30
Main results expected
2026-05-31
Results posted
Not yet
Record last updated
2025-07-30

What the study is testing

The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy.

The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene.

As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to:

  1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s).
  2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD.
  3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment
  4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.

Where it runs

France (1)
Germany (1)
United States (1)

Open on ClinicalTrials.gov for contacts and eligibility